Details of the Drug

General Information of Drug (ID: DM8RR54)

Drug Name

Yso1

Synonyms

naringenin; 480-41-1; (S)-Naringenin; salipurpol; Salipurol; (S)-5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; Naringenine; pelargidanon; (2S)-Naringenin; naringetol; Asahina; NARIGENIN; 5,7,4'-Trihydroxyflavanone; NSC 11855; CCRIS 5839; (-)-(2S)-Naringenin; C15H12O5; UNII-HN5425SBF2; NSC 34875; HN5425SBF2; CHEBI:17846; AI3-23355; Flavanone, 4',5,7-trihydroxy-; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; (-)-Naringenin; YSO1; EINECS 207-550-2; NSC-11855; 2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; CHEMBL9352; NARINGENIN, (-)-; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)-; DTXSID1022392; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4h-chroman-4-one; (-)-(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; (R,S)-Naringenin; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; BE-14348A; NSC-34875; (S)-2,3-dihydo-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (S)-; (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; SR-01000721771; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; 4',5,7-trihydroxyflavan-4-one; Nari; 2uxu; 4deu; S-Dihydrogenistein; pelargidanon 1602; Spectrum_000247; 4eh3; NARINGENIN [MI]; Spectrum2_000325; Spectrum3_000567; Spectrum4_000124; Spectrum5_001423; NARINGENIN [INCI]; 4',5,7-triOH-Flavone; 4',5,7-Trihydroxyflavanon; SCHEMBL20570; BSPBio_001954; KBioGR_000508; KBioSS_000727; MLS000574861; BIDD:ER0116; DivK1c_000118; SPECTRUM1500746; SPBio_000329; 4',5, 7-Trihydroxyflavanone; DTXCID302392; BDBM23419; HMS500F20; KBio1_000118; KBio2_000727; KBio2_003295; KBio2_005863; KBio3_001454; FTVWIRXFELQLPI-ZDUSSCGKSA-N; NINDS_000118; (2S)-5,7,4'-trihydroxyflavone; AIDS001417; HMS2202M06; (2S)-4',5,7-trihydroxyflavanone; HY-N0100; TNP00287; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one; CCG-38601; LMPK12140001; Phytochemistry 8: 127 (1969); s2394; AKOS016843490; CS-6421; DB03467; FS-4072; SDCCGMLS-0066570.P001; (2S)-4',5,7-trihydroxyflavan-4-one; IDI1_000118; NCGC00016457-01; NCGC00016457-02; NCGC00016457-03; NCGC00017346-01; NCGC00163598-01; 1ST40170; AC-33954; CAS-480-41-1; Flavanone, 4',5,7-trihydroxy- (8CI); SMR000156272; FT-0617134; SW219329-1; C00509; EN300-303163; A827427; Q418374; Q-100666; SR-01000721771-3; SR-01000721771-4; BRD-K08832567-001-02-4; BRD-K08832567-001-06-5; 2,3-Dihydro-5,6-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one,2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)-; 13308-00-4

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C15H12O5
Canonical SMILES: C1C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O
InChI: InChI=1S/C15H12O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-6,13,16-18H,7H2/t13-/m0/s1
InChIKey: FTVWIRXFELQLPI-ZDUSSCGKSA-N

Cross-matching ID

PubChem CID: 439246
TTD ID: D92IRY

References

1	Clinical pipeline report, company report or official report of YSOPIA Bioscience